James Sussman, DO
Allergy & Immunology · Santa Fe, NMNPI 1285624593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 28.8% of the total.
Across 363 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- GSK$1K
- CSL Behring$787
- Sanofi$618
- Grifols USA, LLC$349
- plus $2K from 20 others
What the payments were for
- Consulting fees$210%
- Food & beverage$8,75196%
- Education$3244%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 98 | $2,624 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $1,227 |
| GSK | 45 | $1,127 |
| CSL Behring | 22 | $787 |
| Sanofi | 22 | $618 |
| Grifols USA, LLC | 15 | $349 |
| Incyte Corporation | 16 | $347 |
| Amgen(2 entities) | 4 | $270 |
| Regeneron Healthcare Solutions, Inc. | 9 | $269 |
| Novartis | 11 | $222 |
| Shire North American Group Inc | 2 | $197 |
| Pharming Healthcare, Inc. | 5 | $147 |
| Blueprint Medicines Corporation | 6 | $131 |
| Sanofi-aventis U.S. LLC | 3 | $126 |
| Biocryst US Sales Co., LLC | 4 | $119 |
| Boehringer Ingelheim | 6 | $108 |
| Genentech USA, Inc. | 3 | $70 |
| Bio Products Laboratory USA, Inc. | 5 | $69 |
| Tersera Therapeutics LLC | 3 | $59 |
| Optinose US, Inc. | 4 | $57 |
| AbbVie | 3 | $55 |
| ADMA Biomanufacturing LLC | 2 | $36 |
| Merck | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 36 | $169,128 |
| Dupixent SyringeDupilumab | 27 | $154,772 |
| HyqviaIgg/Hyaluronidase,recombinant | 12 | $85,750 |
| NucalaMepolizumab | 16 | $59,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $48,664 |
| XolairOmalizumab | 16 | $48,376 |
| Spiriva RespimatTiotropium Bromide | 30 | $21,612 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $17,899 |
| DuleraMometasone/Formoterol | 17 | $8,026 |
| Arnuity ElliptaFluticasone Furoate | 19 | $7,124 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $5,727 |
| Epinephrine | 26 | $5,359 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,634 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,447 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,127 | $136,940134 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $1,227 | $85,75012 claims |
| Boehringer IngelheimSpiriva Respimat | $108 | $21,61230 claims |
| MerckDulera | $30 | $8,02617 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $22 | $5,72714 claims |
| AstraZenecaSymbicort | $2,624 | $4,63415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Santa Fe
- Corey ClaySanta Fe$11K
- Janna TuckSanta Fe$4K
- Michael RuppLas Cruces$41K
- Amanda Grippen GoddardAlbuquerque$14K
- Jack GhablyAlbuquerque$14K
- Shanze WangAlbuquerque$12K
- Osman DokmeciAlbuquerque$12K
- Teresa Jenkins-MccordAlbuquerque$10K
- Todd FunkhouserLas Cruces$7K
- Steven TolberAlbuquerque$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.